Dan Purser: Redefining Hyperhomocysteinemia Through 22 Critical SNPs
Dan Purser, Co-Founder of AO Biologix, LLC, shared a post on LinkedIn:
“Open Evidence AI finding—’The medical literature confirms that functional glutathione reduces cytokine formation at the monocyte level (Frontiers in Immunology, 2019)’
The ultimate guide to homocysteine: The Purser Model and The 60% Calamity
A Medical Manifesto for the 21st Century By Dan C. Purser
Introduction: The Semmelweis Moment
In 1847, Ignaz Semmelweis discovered that simple hand-washing could virtually eliminate childbed fever.
He was mocked, hounded, and eventually marginalized by an establishment that found his discovery too disruptive to the status quo.
Today, we face a similar ‘Semmelweis Moment.’
For nearly a century, medicine has viewed Hyperhomocysteinemia (HHcy) as a metabolic marker—a number to be ‘lowered’ with simple B-vitamins.
We were wrong.
After treating over 25,000 patients, I am declaring a national health calamity:
50–60% of the U.S. population is standing in the path of cytokine destruction that standard medicine simply cannot see.
Chapter 1: The Bull Elephant (Why 38.8% is a Lie)
Standard medical texts quote a comfortable statistic: 38.8% of the population has a homocysteine problem.
This figure is a relic of an era when we only looked at just a few genes: MTHFR C677T, A1298C, CBS and maybe MTRR, or MTR.
The Purser Model reveals a much darker reality.
By mapping the full genetic architecture, we have identified 22 specific homozygous SNPs—lifelong genetic ‘breaks’—that dictate a patient’s inflammatory setpoint.
When you account for this complete architecture, the number of affected individuals skyrockets to 60% of our civilization.
This is the bull elephant in the china shop, and it is leaving a trail of strokes, heart attacks, and kidney failure in its wake.”
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 26, 2026, 18:28Daniel Pereira Monteiro: Why Is Beta Thalassaemia Major so Severe?
-
Jun 26, 2026, 18:27Pradip Pawar: Cell and Gene Therapy – Transforming Medicine in the 21st Century
-
Jun 26, 2026, 18:26Aviva Schwartz: How Can We Better Protect Patients After an Ischemic Stroke?
-
Jun 26, 2026, 18:25Does Reversing Factor Xa Inhibitors Really Carry as Much Thrombotic Risk as We Think? – RPTH Journal
-
Jun 26, 2026, 18:25Akshat Jain: Novel Therapies in Childhood Blood and Cancer Disorders
-
Jun 26, 2026, 16:57Abdul Muqtadir Abbasi: Anticoagulation in DVT Patients With Hidden Varices Requires Extreme Caution
-
Jun 26, 2026, 16:42Anesa Mulabecirovic: Why Von Willebrand Disease Takes Years to Diagnose in Women
-
Jun 26, 2026, 16:32Kaitlin Lichty: A New Identity Reflecting a Shared Legacy of Bleeding Disorders
-
Jun 26, 2026, 16:07Toong Youttananukorn: The WFH Registry Driving Better Care and Advocacy